LOW SERUM 25-HYDROXYVITAMIN D LEVELS IN PATIENTS WITH BENIGN PAROXYSMAL POSITIONAL VERTIGO

Materials and Methods: 109 patients with BPPV who admitted to our clinic between the January of 2015 and the February of 2018 and 80 patients without a history of dizziness or imbalance during the last one year before admission were included in this study and 25-hydroxytamine D levels were analyzed. Ki- and T-test were used for statistical evaluations.

Results: The mean serum 25-OH vit D levels were measured as 17.9 ± 9.58 ng / mL and 21.09 ± 7.45 ng / mL in the BPPV (109) and control group (80), respectively. Serum 25-OH vit D levels were statistically significantly lower in the BPPV group (p = 0.014). Serum 25-OH vit D levels were lower (<20 ng / mL) in 112 (59.2%) of 189 patients were included in our study. Low Serum 25-OH vit D levels were found in 73 (67%) BPPV patients group. Low Serum 25-OH vit D levels were found in 39 (48.8%) control group. Low serum 25-OH vit D ratio was statistically significantly higher in the BPPV group than in the controls. At the same time, the patients with low serum 25-OH vit D levels were found to be twice as risky as BPPV (p = 0.012, 95% CI = 1.17-3.86, OR = 2.13)

Conclusion: Serum 25-hydroxyvitamin D (25-OH vit D) levels were compared in patients with benign paroxysmal positional vertigo (BPPV) and control group without vestibular complaints, and it was statistically significantly lower in the BPPV patients. It also has been found that low Serum 25-OH vit D levels may be an independent the risk factor for the development of BPPV. However, it is not known whether the disease has improved with replacement therapy. In this respect, prospective studies is needed to evaluate symptomatic improvements, frequency of attacks and the recurrence of the disease after replacement therapy in patients with BPPV deficiency of vitamin D. Keywords : Benign paroxysmal positional vertigo, 25-hydroxyvitamin D, vestibular system